Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer

S. Rao; E. Samalin-Scalzi; L. Evesque; M. Ben Abdelghani; F. Morano; A. Roy; L. Dahan; S. Tamberi; A.S. Dhadda; M.G. Zampino; N. Casanova; R. Guimbaud; A. Lievre; J. Maurel; P. Zhang; M. C. Munteanu; M. Jones; C. de la Fouchardiere; A. Takashima; M. Fakih; J. Spano

doi:10.1016/j.annonc.2026.04.016

Key Points

This research aims to evaluate the survival outcomes of retifanlimab combined with carboplatin and paclitaxel in patients with first-line advanced squamous anal cancer.
Phase 3 trial design
Participants received retifanlimab plus carboplatin and paclitaxel
Study conducted globally, including Australia.
The combination therapy improved overall survival rates in the treatment group compared to historical controls.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Phase 3 trial investigates survival outcomes of retifanlimab with carboplatin-paclitaxel in advanced squamous anal cancer, suggesting a potential treatment option.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rao et al. (2026) studied this question.

synapsesocial.com/papers/69fd7ddcbfa21ec5bbf060ab https://doi.org/10.1016/j.annonc.2026.04.016

View Full Paper

Ask AI

Bookmark

Share

Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from Annals of Oncology

Keep reading

More related papers

More from Annals of Oncology